-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
315 ，，。
35，
，，、、、。
，，，，。
Insight， 15 ，， 35 。
（：insight）
，，：
In the 4+7 volume pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
However, it is foreseeable that the selection of varieties purchased in quantity has gradually tilted towards injection formulations: in the fourth batch of national collections, doxofylline injection, ambroxol hydrochloride injection, parecoxibna for injection, The inclusion of multiple injections such as bivalrudine for injection and pantoprazole sodium for injection is a clear signal.
Many provinces have tested the water
At the earliest, Shanxi Province announced the results of the first batch of drug group alliances to be selected for centralized procurement.
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In October, the People's Government of Shandong Province issued the "Notice on Issuing the Implementation Plan for the Centralized Purchase of Drugs and High-value Medical Consumables in Shandong Province", including aspirin, nifedipine, metoprolol, flunarizine, and omeprazole , Rabeprazole, compound glycyrrhizin, lansoprazole, levamlodipine are commonly used varieties.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
Statistics show that injections account for more than 60% of the pharmaceutical market in China's public hospitals .
Among them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
Among them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
In 2019, the scale of China's injection drugs reached 635.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
According to data from Minai.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
According to policy requirements, there are 3 or more manufacturers that meet the requirements of centralized procurement of qualified drugs (including original research drugs or reference preparations, drugs that have passed consistency evaluation, drugs approved according to the new classification, and drugs in the "China List of Listed Drugs").
The drug will be included in the centralized procurement catalog.
The drug will be included in the centralized procurement catalog.
With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
What issues should be paid attention to when injections are used in centralized procurement?
The market involved in injections exceeds 100 billion yuan.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
It is understood that, as a high-risk dosage form, injections are directly injected into blood vessels, tissues or organs, which are absorbed quickly and act quickly.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
The Drug Evaluation Center of the State Food and Drug Administration and the National Adverse Drug Reaction Monitoring Center released the "2019 National Adverse Drug Reaction Monitoring Report" showing that 477,000 new and serious adverse reaction/event reports were received in 2019, accounting for the total number of reports 31.
5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
The incidence of adverse reactions of injections is still relatively high.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
It is also necessary to pay attention to a figure.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
In the distribution of over-evaluated injection therapy in 2020, anti-tumor and immunomodulators accounted for 15.
48%, second only to nervous system drugs and systemic anti-infective drugs.
48%, second only to nervous system drugs and systemic anti-infective drugs.
This means that injections, especially drugs with a narrow therapeutic window, are included in the collection, and more attention should be paid to safety and effectiveness.
In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
Medical Network News on March 15 With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
35 injections, meeting the requirements of centralized procurement
Recently, the State Food and Drug Administration issued information on the collection of drug approval documents, flumazenil injection, amlodipine besylate dispersible tablets, piperacillin sodium and tazobactam sodium for injection, and cefminox sodium for injection.
This variety ushered in the first over-assessment enterprise.
This variety ushered in the first over-assessment enterprise.
In addition, Metronidazole Sodium Chloride Injection has been evaluated for the second time.
At present, Tianjin Baxter Medical has been approved for import in China.
In addition, the evaluated Kelun Pharmaceutical and Shijiazhuang Four Medicines have been qualified for centralized procurement.
condition.
At present, Tianjin Baxter Medical has been approved for import in China.
In addition, the evaluated Kelun Pharmaceutical and Shijiazhuang Four Medicines have been qualified for centralized procurement.
condition.
According to Insight database statistics, 15 injections have been collected in the first four batches of centralized procurement.
With the acceleration of the injection consistency evaluation review and approval, there are currently 35 injections that meet the requirements of centralized procurement.
With the acceleration of the injection consistency evaluation review and approval, there are currently 35 injections that meet the requirements of centralized procurement.
(Image source: insight database)
For a long time, the core focus of national centralized procurement has been oral preparations, which can be seen from the selection of varieties in the previous batches:
In the 4+7 volume pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
However, it is foreseeable that the selection of varieties purchased in quantity has gradually tilted towards injection formulations: in the fourth batch of national collections, doxofylline injection, ambroxol hydrochloride injection, parecoxibna for injection, The inclusion of multiple injections such as bivalrudine for injection and pantoprazole sodium for injection is a clear signal.
Many provinces have tested the water
At the earliest, Shanxi Province announced the results of the first batch of drug group alliances to be selected for centralized procurement.
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In October, the People's Government of Shandong Province issued the "Notice on Issuing the Implementation Plan for the Centralized Purchase of Drugs and High-value Medical Consumables in Shandong Province", including aspirin, nifedipine, metoprolol, flunarizine, and omeprazole , Rabeprazole, compound glycyrrhizin, lansoprazole, levamlodipine are commonly used varieties.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
Statistics show that injections account for more than 60% of the pharmaceutical market in China's public hospitals .
Among them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
Among them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
In 2019, the scale of China's injection drugs reached 635.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
According to data from Minai.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
According to policy requirements, there are 3 or more manufacturers that meet the requirements of centralized procurement of qualified drugs (including original research drugs or reference preparations, drugs that have passed consistency evaluation, drugs approved according to the new classification, and drugs in the "China List of Listed Drugs").
The drug will be included in the centralized procurement catalog.
The drug will be included in the centralized procurement catalog.
With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
What issues should be paid attention to when injections are used in centralized procurement?
The market involved in injections exceeds 100 billion yuan.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
It is understood that, as a high-risk dosage form, injections are directly injected into blood vessels, tissues or organs, which are absorbed quickly and act quickly.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
The Drug Evaluation Center of the State Food and Drug Administration and the National Adverse Drug Reaction Monitoring Center released the "2019 National Adverse Drug Reaction Monitoring Report" showing that 477,000 new and serious adverse reaction/event reports were received in 2019, accounting for the total number of reports 31.
5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
The incidence of adverse reactions of injections is still relatively high.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
It is also necessary to pay attention to a figure.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
In the distribution of over-evaluated injection therapy in 2020, anti-tumor and immunomodulators accounted for 15.
48%, second only to nervous system drugs and systemic anti-infective drugs.
48%, second only to nervous system drugs and systemic anti-infective drugs.
This means that injections, especially drugs with a narrow therapeutic window, are included in the collection, and more attention should be paid to safety and effectiveness.
In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
Medical Network News on March 15 With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
35 injections, meeting the requirements of centralized procurement
35 injections, meeting the requirements of centralized procurement Recently, the State Food and Drug Administration issued information on the collection of drug approval documents, flumazenil injection, amlodipine besylate dispersible tablets, piperacillin sodium and tazobactam sodium for injection, and cefminox sodium for injection.
This variety ushered in the first over-assessment enterprise.
This variety ushered in the first over-assessment enterprise.
In addition, Metronidazole Sodium Chloride Injection has been evaluated for the second time.
At present, Tianjin Baxter Medical has been approved for import in China.
In addition, the evaluated Kelun Pharmaceutical and Shijiazhuang Four Medicines have been qualified for centralized procurement.
condition.
At present, Tianjin Baxter Medical has been approved for import in China.
In addition, the evaluated Kelun Pharmaceutical and Shijiazhuang Four Medicines have been qualified for centralized procurement.
condition.
According to Insight database statistics, 15 injections have been collected in the first four batches of centralized procurement.
With the acceleration of the injection consistency evaluation review and approval, there are currently 35 injections that meet the requirements of centralized procurement.
With the acceleration of the injection consistency evaluation review and approval, there are currently 35 injections that meet the requirements of centralized procurement.
(Image source: insight database)
For a long time, the core focus of national centralized procurement has been oral preparations, which can be seen from the selection of varieties in the previous batches:
In the 4+7 volume pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
pharmnet. com.
cn/news/yyzb/" target="_blank">purchase , there are 25 shortlisted varieties.
Only 3 varieties of pemetrexed disodium for injection, flurbiprofen axetil injection and dexmedetomidine hydrochloride are injection varieties, and the oral dosage accounted for Than 88%.
Among the 32 species collected in the second batch of national collections, only paclitaxel for injection is an injection, and oral dosage accounts for 96.
87%.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
However, it is foreseeable that the selection of varieties purchased in quantity has gradually tilted towards injection formulations: in the fourth batch of national collections, doxofylline injection, ambroxol hydrochloride injection, parecoxibna for injection, The inclusion of multiple injections such as bivalrudine for injection and pantoprazole sodium for injection is a clear signal.
Many provinces have tested the water
Many provinces have tested the water At the earliest, Shanxi Province announced the results of the first batch of drug group alliances to be selected for centralized procurement.
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In this centralized procurement catalog, 21 drugs are all injections.
The selection rules in Shanxi Province are relatively simple, that is, "winning the bid at the lowest price.
"
In October, the People's Government of Shandong Province issued the "Notice on Issuing the Implementation Plan for the Centralized Purchase of Drugs and High-value Medical Consumables in Shandong Province", including aspirin, nifedipine, metoprolol, flunarizine, and omeprazole , Rabeprazole, compound glycyrrhizin, lansoprazole, levamlodipine are commonly used varieties.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
It is worth noting that among the 40 varieties, there are 27 injection forms, 13 oral forms, and injection forms account for more than Two thirds.
Statistics show that injections account for more than 60% of the pharmaceutical market in China's public hospitals .
Among them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
Hospital hospital hospitalAmong them, chemical injections even reach 70%, and injections have more than 33,000 approvals.
In 2019, the scale of China's injection drugs reached 635.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
493 billion yuan.
Although the growth rate of the injection market slowed down due to the "anti-injection restriction order", it still maintained absolute growth.
That is to say, the high amount of injection, the large amount, and the basic requirements of mass procurement, will be the main force of centralized procurement in the future.
According to data from Minai.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
com, in 2020, a total of 84 injections (256 product regulations) in China have passed the consistency evaluation of generic injections deemed to have passed the National Food and Drug Administration.
Among them, neurological drugs, systemic anti-infective drugs, and anti-infective drugs Tumor drugs and immunomodulators are the mainstays, accounting for over 15%.
The scale of these three areas in the terminal market of China's public medical institutions has exceeded 100 billion yuan in 2019.
According to policy requirements, there are 3 or more manufacturers that meet the requirements of centralized procurement of qualified drugs (including original research drugs or reference preparations, drugs that have passed consistency evaluation, drugs approved according to the new classification, and drugs in the "China List of Listed Drugs").
The drug will be included in the centralized procurement catalog.
Medicine, medicine, medicineThe drug will be included in the centralized procurement catalog.
With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
What issues should be paid attention to when injections are used in centralized procurement?
The market involved in injections exceeds 100 billion yuan.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
Unlike solid preparations, injections have complex processes and many influencing factors, and require more careful attention.
It is understood that, as a high-risk dosage form, injections are directly injected into blood vessels, tissues or organs, which are absorbed quickly and act quickly.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
Especially for intravenous injections, the drug directly enters the blood circulation and exerts its efficacy.
It is a high-risk dosage form in clinical use.
, Its technical requirements for R&D and production are also stricter.
The Drug Evaluation Center of the State Food and Drug Administration and the National Adverse Drug Reaction Monitoring Center released the "2019 National Adverse Drug Reaction Monitoring Report" showing that 477,000 new and serious adverse reaction/event reports were received in 2019, accounting for the total number of reports 31.
5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
Adverse reactions adverse reactions adverse reactions5%.
Among them, there were 156,000 serious adverse reaction/event reports, accounting for 10.
3%, a slight increase from the previous year.
The incidence of adverse reactions of injections is still relatively high.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
In the reports of adverse reactions/events of chemical drugs, 66.
2% were related to injections; in biological preparations, this number was as high as 97.
5%.
In the field of traditional Chinese medicine, the adverse reactions/event reports of injection administration accounted for 45.
5%, of which intravenous infusion accounted for more than 98%.
It is also necessary to pay attention to a figure.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
Among the corresponding proportions of each dosage form in the serious adverse reactions/events related to anti-infective drugs, cardiovascular drugs, anti-tumor drugs and medications for the elderly, anti-tumor injections account for the largest proportion, as high as 89.
5%.
In the distribution of over-evaluated injection therapy in 2020, anti-tumor and immunomodulators accounted for 15.
48%, second only to nervous system drugs and systemic anti-infective drugs.
48%, second only to nervous system drugs and systemic anti-infective drugs.
This means that injections, especially drugs with a narrow therapeutic window, are included in the collection, and more attention should be paid to safety and effectiveness.
In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
Enterprise business enterprise In this context, when medical insurance funds are tight and medical insurance control fees become more stringent, over-rated injections that meet the requirements of centralized procurement may be preferred.
Related companies are also facing opportunities to increase their visibility and market sales.
